Importance of Intermittent Fasting Regimens and Selection of Adequate Therapy on Inflammation and Oxidative Stress in SARS-CoV-2 Infection

Armin Ezzati 1,2, Sara K. Rosenkranz 3* and Benjamin D. Horne 4,5,*

1 Department of Food, Nutrition, Dietetics and Health, Kansas State University, Manhattan, KS 66506, USA
2 Physical Activity and Nutrition Clinical Research Consortium, College of Health and Human Sciences, Manhattan, KS 66506, USA
3 Department of Kinesiology and Nutrition Sciences, University of Nevada Las Vegas, Las Vegas, NV 89154, USA
4 Intermountain Medical Center Heart Institute, Salt Lake City, UT 84107, USA
5 Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA
* Correspondence: benjamin.horne@imail.org or hornebd@stanford.edu; Tel.: +1-801-507-4708; Fax: +1-801-507-4792

Abstract: The unpredictable nature of new variants of coronavirus 2 (SARS-CoV-2)—highly transmissible and some with vaccine-resistance, have led to an increased need for feasible lifestyle modifications as complementary therapies. Systemic inflammation is the common hallmark of communicable diseases like severe coronavirus disease 2019 (COVID-19) and non-communicable chronic diseases (NCDs) such as obesity, cardiovascular diseases (CVD), diabetes mellitus, and cancers, all for which mitigation of severe outcomes is of paramount importance. Dietary quality is associated with NCDs, and intermittent fasting (IF) has been suggested as an effective approach for treatment and prevention of some NCDs, similar to that of caloric restriction. There is a paucity of high-quality data from randomized controlled trials regarding the impact of IF and the intake of specific nutrients on inflammation and post-infection outcomes in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The current review of recent literature was performed to explore the immunomodulatory roles of IF regimens and supplements involving the intake of specific nutrients including vitamins (A, B, C, D, and E), zinc, and nutraceuticals (n-3 polyunsaturated fatty acids, quercetin, and probiotics) on inflammatory and oxidative stress markers, with consideration of how they may be related to SARS-CoV-2.

Keywords: SARS-CoV-2; dietary supplements; intermittent fasting; COVID-19; inflammation; oxidative stress; time-restricted eating; vitamins; nutraceutical; chronic diseases

1. Introduction

A new wave of a subvariant of concern of the “omicron” variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—which poses very high risk of infection—is spreading worldwide, continuing the evolving pandemic that is now in its third year [1]. The efficacy of current vaccines against this heavily mutated variant is still unclear [2]. The unpredictable nature of new variants of SARS-CoV-2 and the poorly characterized and poorly understood post-acute sequelae (PASC) of coronavirus disease 2019 (COVID-19) have led to an increased need for feasible lifestyle modifications as complementary therapies to vaccines to reduce disease severity, particularly given that those effects wane over a period of months [3]. Identification of effective and feasible complementary therapies is critical to provide protection against the severity of both acute and PASC outcomes, since vaccinating a majority of the world population every 6 months or even more frequently is unlikely to be financially or logistically possible.
A key characteristic of severe presentations of acute SARS-CoV-2 infection involves overactive host inflammatory responses, with a substantial proportion of severe outcomes such as hospitalizations and deaths from COVID-19 linked to hyper-inflammation [4]. Inflammation and oxidative stress play pivotal roles in the progression of infectious diseases including COVID-19 [5]. Evidence suggests that high sensitivity (hs) C-reactive protein (CRP), interleukin (IL)-6, and matrix metalloproteinases (MMPs) are among the most important biomarkers of COVID-19 severity, similar to the chronic conditions involved in vascular aging [6–9]. Lactate dehydrogenase (LDH) and hsCRP are also biomarkers of respiratory failure in patients with COVID-19 [10]. Furthermore, it is well established that elevated levels of other inflammatory markers are common in COVID-19 patients. These markers include IL-1β, IL-7, IL-8, IL-18, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, procalcitonin (PCT), serum ferritin, and erythrocyte sedimentation rate (ESR) [11,12].

Interestingly, hs-CRP, IL-6, and many of the other inflammatory biomarkers mentioned above, are also markers of risk in NCDs such as coronary artery disease and diabetes [13–16]. A wealth of evidence indicates that treatments that reduce inflammation, assessed using these biomarkers, also protect against major adverse cardiovascular events [17–19]. Some of these treatments may include simple nutritional therapies such as vitamin D supplementation in patients with vitamin D deficiency [20]. Many studies suggest that a high-quality diet, calorie restriction-induced weight loss (>5%), and intermittent fasting (IF), lower the risk of NCDs including diabetes and coronary artery disease [21–32], which may be due in part to reduction of chronic inflammation. If so, it may also be that IF and some simple specific nutrients may play a role in boosting immunity in response to SARS-CoV-2 infection, as has been hypothesized in previous reviews [33–36]. Yet, there is a paucity of comprehensive data from randomized controlled trials (RCTs) regarding the impact of IF and other simple nutritional therapies on inflammation generally, and specifically related to their effects on responses to SARS-CoV-2. While weight loss is known to reduce inflammation and to control risk factors related to both COVID-19 outcomes and NCDs, some dietary regimens, including IF, may impact inflammation and other pathways independently of weight loss [30,37,38]. The current review of recent literature was performed to explore the immunomodulatory roles of dietary supplements (including some vitamins, minerals, and nutraceuticals) and IF on inflammatory and oxidative stress markers that may be related to SARS-CoV-2 or host responses to infection, and also have some connection to reduction of chronic inflammation linked to NCDs.

2. Methodology of Literature Search

A literature search of the PubMed and Google Scholar databases was conducted to identify peer-reviewed articles published from January 2017 to March 2022 that involved assessments of markers of inflammation or oxidative stress. The search terms for dietary supplementation articles included the following: “vitamin”, “nutrient”, “mineral”, “antioxidant”, “nutraceuticals”, “polyphenols”, “resveratrol”, “quercetin”, “probiotic”, “omega-3”, combined with “infection”, “inflammation”, “inflammatory markers”, “immune response”, “immunity”, “oxidative stress”, “CVD”, “obese adults”, “obesity”, “overweight”, “SARS-CoV-2”, and “COVID-19.” The search terms for intermittent fasting articles included the following: “intermittent fasting”, “alternate-day fasting”, “time-restricted eating”, “5:2 diet”, “Ramadan fasting”, combined with “infection”, “inflammation”, “inflammatory markers”, “immune response”, “immunity”, “oxidative stress”, “CVD”, “obese adults”, “obesity”, “overweight”, “SARS-CoV-2”, and “COVID-19.” Filters were set to allow only “human” studies, and studies written in the “English” language.

3. The Impact of Dietary Supplements on Inflammatory Markers and in Response to SARS-CoV-2

3.1. Vitamins and Minerals

Supplementation with vitamins such as A, B, C, D, and E is thought to play a significant role in the severity of COVID-19 infection by reducing inflammation, time to recovery,
and preventing lung fibrosis [39,40]. To our knowledge, no RCTs have tested the effects of supplementation with vitamin A, B, or C alone, on COVID-19 severity; however, in a 7-day randomized placebo-controlled trial of 60 COVID-19 patients admitted to intensive care unit (ICU), those who received a combination of vitamins A (25,000 IU daily), D (600,000 IU; one dose), E (300 IU twice daily), C (500 mg four times daily), and a B-complex ampule (daily), demonstrated significant reductions in the duration of hospitalization, TNF-α, Il-6, erythrocyte sedimentation and hs-CRP, but not IFN-γ, as compared to a placebo [41]. In contrast, 10-days of standard treatment plus high doses of vitamin C (2 g), Melatonin (6 mg), and Zinc (50 mg), was not effective for lowering inflammatory markers or length of hospitalization in 20 patients with severe COVID-19 [42].

Accumulating data highlight the immunomodulatory role of vitamin D, and link hypovitaminosis D (25 OHD ≤ 20 ng/mL) with hyperinflammation (i.e., the so-called “cytokine storm”) and elevated risk of mortality in patients with COVID-19 [43–46]. Therefore, supplementation with vitamin D is suggested to attenuate the risk of the cytokine storm, and the severity of COVID-19 [43,47]. The impact of vitamin D on inflammatory markers and in response to SARS-CoV-2 infection has been explored in several RCTs (see Table 1). The current state of evidence from RCTs indicates that higher doses of daily intake of vitamin D can reduce the levels of inflammatory markers like IL-6, hsCRP, and time to recovery in COVID-19 patients [48,49]. Ten days of supplementation with 60,000 IU/day of vitamin D in combination with standard treatment significantly reduced IL-6, hsCRP, LDH, ferritin, and Neutrophil/Lymphocyte ratio, in 87 hospitalized COVID-19 patients with vitamin D deficiency (D < 30 ng/m) as compared with the controls, who received standard treatment for 8 to 10 days [49]. Similarly, in a 2-week trial, oral intakes of two different doses of vitamin D3 (5000 IU vs. 1000 IU) resulted in significant decreases in plasma IL-6 versus baseline, with no between group differences, while hsCRP levels remained unchanged in both groups [48]. Furthermore, time required for resolving cough symptoms with D3 supplementation (5000 IU) was significantly shorter compared to the comparison group [48]. Rastogi et al. investigated the effects of high-dose vitamin D supplementation (60,000 IU) as compared with control in 40 SARS-CoV-2 RNA positive individuals. Patients with vitamin D deficiency (25(OH) D < 20 ng/mL) who were positive for SARS-CoV-2 RNA, with mild or no symptoms, significantly improved with regard to viral SARS-CoV-2 RNA clearance (62.5% vs. 20.8%) and fibrinogen levels [50]. In contrast, a single dose of vitamin D was ineffective for lowering inflammatory markers and for the treatment of patients with severe COVID-19 [51–53].

Evidence for the potential role of zinc supplementation for COVID-19 infection is inconclusive [54–56]; with only one 28-day RCT of 191 patients with COVID-19 having investigated the effects of zinc supplementation (50 mg of zinc twice daily) combined with chloroquine/hydroxychloroquine (CQ/HCQ) on inflammatory markers. The study results indicated no significant changes in hs-CRP levels or clinical recovery time [57].
| Authors/Year/Country | Duration | Participants | Study Design | TNF-α | IL-1β | IL-4 | IL-6 | IL-10 | CRP | IFN-γ | Other Outcomes |
|----------------------|----------|--------------|--------------|-------|-------|------|------|-------|-----|-------|----------------|
| Rastogi et al., 2020 [50] India | 7-d | 40 SARS-CoV-2 RNA positive individuals | RCT: 1. Daily oral cholecalciferol (60,000 IU) with therapeutic target 25(OH)D > 50 ng/mL 2. Control | - | - | - | - | - | Ø | - | ↓† Fibrinogen ↑† Negative conversion of SARS-CoV-2 RNA (62.5% vs. 20.8%) |
| Murai et al., 2021 [53] Brazil | - | 237 patients hospitalized for moderate to severe COVID-19 | RCT: 1. A single oral dose of 200,000 IU of vit. D3 2. Placebo | - | - | - | - | - | Ø | - | Ø Same LOS (median of 7.0 vs. 7.0 days) |
| Lakkireddy et al., 2021 [49] India | 8–10-d | 87 Patients hospitalized for COVID-19 Vit. D < 30 ng/mL | RCT: 1. 60,000 IU/day of oral vitamin D + standard treatment 2. Only standard treatment | - | - | - | 1. ↓† 2. Ø | 1. ↓ 2. *† | - | - | ↓*† LDH, ferritin, N/L ratio |
| Beigmohammadi et al., 2021 [41] Iran | 7-d | 60 ICU-admitted COVID-19 patients | RCT: 1. Oral Vit. A (25,000 IU) daily, vit.D (600,000 IU; one dose), vit. E (300 IU twice daily), vit. C (500 mg four times daily), and one amp daily of B complex 2. Placebo | 1. ↓*† 2. ↓* | - | - | 1. ↓* 2. Ø | 1. ↓* 2. ↓* | - | ↓† Hospitalization rate and ESR in treatment group |
| Sabico et al., 2021 [48] Saudi Arabia | 14-d | 69 patients COVID-19 and sub-optimal vit. D status | RCT: 1. Oral vit. D3 (5000 IU) 2. Oral vit. D3 (1000 IU) | - | - | - | 1. ↓* 2. Ø | 1. Ø | - | - | ↓† Time to recovery in resolving cough with D3 (5000 IU) vs. D3 (1000 IU) |
| Abd-Elsalam et al., 2021 [57] Egypt | 4 weeks | 191 patients with COVID-19 | RCT: 1. CQ/HCQ + 220 mg of zinc sulfate twice daily 2. HCQ only | - | - | - | - | Ø | - | Ø Clinical efficacy of HCQ |
| Di Pierro et al., 2021 [58] Italy | 2 weeks | 42 COVID-19 outpatients | RCT: 1. Quercetin (500 mg/day (first week) and of 1000 mg/day (second week) 2. Standard of care | - | - | - | - | Ø | - | ↓† LOS, virus clearance, symptoms frequency, LDH, ferritin |
| Authors/Year/Country | Duration | Participants | Study Design | TNF-α | IL-1β | IL-4 | IL-6 | IL-10 | CRP | IFN-γ | Other Outcomes |
|----------------------|----------|--------------|--------------|------|------|-----|-----|------|-----|------|------------------|
| Doae et al., 2021 [59] Iran | 2 weeks | 128 critically ill COVID-19 patients | RCT: 1. 1000 mg omega-3 daily (400 mg EPAs and 200 mg DHAs) 2. Control | - | - | - | - | - | - | - | ↑ + 1-month survival rate, pH, HCO₃, and Be ↓ + Levels of BUN, Cr, and K in the treatment group |
| Darban et al., 2021 [42] Iran | 10-d | 20 patients with severe COVID-19 | Pilot RCT: 1. Standard care + oral zinc sulfate (220 mg containing 50 mg zinc), oral melatonin (6 mg, q6hr), and intravenous vit. C (2 g) 2. Standard care alone | - | - | - | - | - | - | - | 1. ↓* 2. ↓* | Ø LOS |
| Sedighian et al., 2021 [60] Iran | 2 weeks | 30 patients with COVID-19 | Single blind RCT: 1. Hydroxychloroquine + 2 g DHAs and EPAs 2. Hydroxychloroquine | - | - | - | - | - | - | - | 1. ↓† | Ø Body pain and fatigue in the treatment group Ø Olfactory |
| Cannata-Andia et al., 2022 [52] Spain | - | 543 patients with moderate to severe COVID-19 | RCT: 1. A single-oral bolus of 100,000 IU of cholecalciferol 2. Control | - | - | - | Ø | - | Ø | - | Ø Hospitalization rate and death |
| Shohan et al., 2022 [61] Iran | 7-d | 60 patients with severe COVID-19 | RCT: 1. Quercetin (1000 mg daily) + antiviral drugs 2. Antiviral drugs | ↓* | ↓* | - | ↓† | - | ↓† | - | ↓† | Ø Mortality, duration of ICU-admission |
| Authors/Year/Country | Duration | Participants | Study Design | TNF-α | IL-1β | IL-4 | IL-6 | IL-10 | CRP | IFN-γ | Other Outcomes |
|----------------------|----------|--------------|--------------|--------|-------|------|------|-------|-----|-------|----------------|
| Pimentel et al., 2022 [62] Brazil | 7-d | 43 adult patients with COVID-19 | RCT: 1. Two 200 mL units of high-protein nutritional supplement (arginine, omega-3 fatty acids and nucleotides) over 24 h 2. Two 200 mL units of high-protein nutritional supplement alone | - | - | - | - | - | 1. ↓ † 2. Ø | - | ↑ Lymphocytes in the treatment group ↓ Lymphocytes in the control group |
| Fernandes et al., 2022 [51] Brazil | - | 200 patients with moderate to severe COVID-19 | RCT: 1. Single oral dose of vit. D3 (200,000 IU) 2. Placebo | Ø | Ø | Ø | Ø | Ø | - | Ø | - |
| Gutiérrez-Castrellón et al., 2022 [63] Spain | 30-d | 293 COVID-19 outpatients | RCT: 1. Probiotic (Lactiplantibacillus plantarum stains KABP022, KABP023 and KABP033 = Pediococcus acidilactici strain KABP021) 2. Placebo | - | - | - | - | - | 1. ↓ † hs-CRP Only on day 15 | ↓ † Complete remission (53.1% in probiotic group vs. 28.1% in placebo; p < 0.001) |

*: Not measured. Ø: Non-significant difference between groups. * p < 0.05, Significantly different from baseline (within group effect). † p < 0.05, Significantly different from the control or comparison group. TNF-α: tumor necrosis factor α; IL-1β: Interleukin-1β; IL-4: Interleukin-4; IL-6: Interleukin-6; IL-10: Interleukin-10; IFN-γ: Interferon gamma; CQ/HCQ: Chloroquine/hydroxychloroquine; HCQ: Hydroxychloroquine; ALP: Alkaline phosphatase; Lactate dehydrogenase; Be: Base excess; BUN: Blood urea nitrogen; Cr: creatinine; LOS: Length of hospital stay; LDH: Lactate dehydrogenase; N/L ratio: Neutrophil/Lymphocyte ratio; ESR: Erythrocyte sedimentation rate; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid.
3.2. n-3 Polyunsaturated Fatty Acids (PUFAs)

It is well known that n-3 PUFAs including eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA) have anti-inflammatory properties [64–66]. The current state of evidence from RCTs suggests that supplementation with n-3 fatty acids appears to be effective for alleviating clinical symptoms and inflammatory responses in patients with COVID-19 (see Table 1). Three of the trials included in this review investigated the efficacy of n-3 PUFAs for COVID-19 outcomes [59,60,62]. Supplementation with daily omega-3 capsules (1000 mg; 400 mg EPAs and 200 mg DHAs) for 2 weeks resulted in significantly higher 1-month survival rates in 128 ICU patients with COVID-19 when compared to the control patients [59]. The study also reported meaningful improvements in respiratory and renal function parameters such as arterial PH, bicarbonate, and other base excess in the treatment group. Similarly, DHA and EPA supplementation (2 g) plus hydroxychloroquine, significantly reduced hs-CRP, body pain, and fatigue compared to hydroxychloroquine alone in 30 patients with COVID-19 [60]. In agreement with those results, a 7-day trial in 43 patients with COVID-19 who were treated with oral immuno-nutrient supplements containing arginine, omega-3 fatty acids, and nucleotides (Two 200 mL units over 24 h), indicated meaningful reductions in hs-CRP when compared with the patients who were given only high-protein nutritional supplements (Two 200 mL units) [62].

3.3. Quercetin

Quercetin—a polyphenol with antioxidant and anti-inflammatory properties—is widely known to have favorable effects on inflammation and infection [67–69]. Di Pierro et al. reported that in 42 outpatients with COVID-19, two weeks of quercetin therapy (500–1000 mg daily) significantly diminished the rate (−68.2%) and length (−76.8%) of hospitalization, the need for non-invasive oxygen therapy (−93.3%), and the mortality rate (although events were very limited: none vs. 3 people) compared to the control (standard of care) [58]. Furthermore, significant reductions in LDH and ferritin levels were reported in the treatment group vs. control, while hs-CRP remained unchanged [58]. Unlike the 2-week trial by Di Pierro et al., a shorter 7-day RCT including 60 patients with severe COVID-19, treated with daily quercetin (1000 mg) along with antiviral drugs, compared with control (only antiviral drugs), did not alter mortality or ICU-admission duration significantly. Notably, significant reductions in inflammatory markers such as TNF-α, IL-1β, IL-6, hs-CRP, ALP, and LDH were shown in the treatment group as compared to the control or baseline [61].

3.4. Probiotics

High quality evidence from systematic reviews and meta-analyses of RCTs, indicates that probiotics may have a favorable role for responses to infections [70]. In a recent one-month RCT of 293 outpatients with COVID-19, supplementation with four-strain probiotics consisting of Lactiplantibacillus plantarum KABP033 (CECT30292), L. plantarum KABP022 (CECT7484), L. plantarum KABP023 (CECT7485), and Pediococcus acidilactici KABP021 (CECT7483), produced significant reductions in remission rates vs. placebo (53.1% in probiotic group vs. 28.1% in placebo) [63].

4. The Potential Impact of IF on Inflammatory Markers

To date, no RCTs have investigated the effects of IF on SARS-CoV-2 infection or severity of COVID-19 outcomes, although epidemiologic evidence regarding periodic fasting suggests that fasting in some forms may prevent severe COVID-19 outcomes such as hospitalization and death [71], perhaps in part, through the control of hyper-inflammation. The impacts of IF on markers of inflammation and oxidative stress are summarized below:
4.1. Interleukins

Current evidence from RCTs reveals that time-restricted eating (TRE) may be effective for reducing interleukins IL-1β, IL-6 and IL-8 (see Table 2.) Of the 11 TRE trials included in this review, only one trial assessed IL-1β levels. This 12-month trial of 20 healthy athletes reported significant reductions in both IL-1β and IL-6 levels in the TRE group (3 meals; 1 p.m., 4 p.m., and 8 p.m.) compared with normal diet control group (3 meals; 8 a.m., 1 p.m., and 8 p.m.) [72]. However, IL-6 levels have remained unchanged in other TRE studies [30,32,73,74]. Xie et al. conducted a 5-week trial examining plasma IL-8 levels in 82 healthy participants who had normal weight, when following early TRE (6 a.m.–3 p.m.), mid-day TRE (11 a.m.–8 p.m.), and as compared with an ad libitum intake control group, and showed a significant reduction in IL-8 levels vs. control when following early TRE [75]. Similarly, results of observational and clinical trials from Ramadan IF (fasting from sunrise to sunset) studies suggest that this form of IF may be effective for counterbalancing inflammatory interleukins such as IL-1β, IL-2, IL-6, IL-8, and IL-10 [76–85] (see Table 3). In a one-month RCT in 28 men with obesity conducted by Zouhal et al., Ramadan IF produced meaningful reductions in plasma IL-6 levels vs. control. Unlike the results from TRE and Ramadan IF trials, other popular types of IF, including alternate-day fasting (ADF) and twice-weekly 24-h fasting (commonly called “5:2 diets”) have not shown effects on inflammatory interleukins including IL-1β, IL-6, and IL-10 [28,86–92] (see Table 4). The effects of 24-h prolonged fasting on inflammatory markers has been tested in two single-arm trials by Han et al. with results indicating significant improvements in IL-1β, IL-2, IL-4, IL-5, IL-13, IL-17 and IL-22 as compared to postprandial responses measured 3 h after refeeding with isocaloric breakfast meal (500 kcal) [93,94].
Table 2. Summary of clinical trials on the impact of time-restricted eating (TRE) on inflammatory markers and oxidative stress.

| Authors/Year/Country | Duration | Participants | Study Design | 8-Isoprostane | TNF-α | IL-1β | IL-6 | IL-8 | CRP | IGF-1 |
|----------------------|----------|--------------|--------------|---------------|-------|-------|------|------|-----|-------|
| Sutton et al., 2018 [30] US | 5 weeks | 12 prediabetic men | RCT crossover: 1. Eucaloric eTRE (6-hr eating window, last meal before 3 pm) without weight loss 2. Control (12-hr. eating window) | 1. ↓14%† 2. Ø | - | - | Ø | - | Ø | - |
| Jamshed et al., 2019 [37] US | 4-day | 11 overweight adults | RCT crossover: 1. eTRE (8 a.m.–2 p.m.) 2. Control (8 a.m.–8 p.m) | - | - | - | - | - | Ø |
| Martens et al., 2020 [73] US | 6 weeks | 22 healthy non-obese older adults | RCT: 1. Eucaloric TRE (16/8)- without weight loss 2. Control | - | - | - | Ø | - | Ø |
| Wilkinson et al., 2020 [95] US | 12 weeks | 19 adults with MetSyn | Single arm: 10-h TRE (self-selected eating window) | - | - | - | - | - | Ø |
| Cienfuegos et al., 2020 [32] US | 8 weeks | 49 obese adults | RCT: 1. 4-h TRE (3–7 p.m.) 2. 6-h TRE (1–7 p.m.) 3. Control | 1. ↓37% *† 2. ↓34% *† 3. Ø | - | - | - | - | - |
| McAllister et al., 2020 [96] US | 4 weeks | 22 men BMI: 28.5 ± 8.3 | RCT: 16:8 TRE 1. Isocaloric TRE 2. Ad libitum TRE | - | - | - | - | - | 1. ↓45† hs-CRP | |
| Moro et al., 2020 [74] Italy | 4 weeks | 16 elite under 23 cyclists | RCT: 1. TRE (10 a.m.–6 p.m.) 2. Control (7 a.m.–9 p.m.) | - | Ø | - | Ø | - | 1. ↓14% * 2. Ø |
| Moro et al., 2021 [72] Italy | 12 months | 20 healthy resistance-trained males | RCT: 1. mTRE (3 meals;1 p.m.,4 p.m. and 8 p.m.) 2. Control (8 a.m., 1 p.m., and 8 p.m.) | - | 1. ↓*† 2. Ø | 1. ↓*† 2. Ø | 1. ↓*† 2. Ø | - | 1. ↓*† 2. ↑† |
### Table 2. Cont.

| Authors/Year/Country | Duration | Participants | Study Design | 8-Isoprostane | TNF-α | IL-1β | IL-6 | IL-8 | CRP | IGF-1 |
|----------------------|----------|---------------|--------------|---------------|-------|-------|------|------|-----|-------|
| Li et al., 2021 [97] China | 5 weeks | 15 overweight and obese women with PCOS | Single arm: eTRE (8 am–4 pm) 1-week baseline weight stabilization + 5-week trial | - | - | - | - | - | ↓42% * hs-CRP | ↑34% * |
| Kotarsky et al., 2021 [98] US | 8 weeks | 21 overweight and obese adults | RCT: 1. mTRE (12–8 p.m.) + concurrent exercise training 2. Normal eating + concurrent exercise training | - | - | - | - | - | Ø hs-CRP | - |
| Xie et al., 2022 [75] China | 5 weeks | 82 healthy adults | RCT: 1. e-TRE (6 a.m.–3 p.m.) 2. mTRE (11 a.m.–8 p.m.) 3. Control (ad lib intake) | - | 1. † | 2. Ø | - | - | 1. † | Ø |

*: Not measured. Ø: Non-significant difference between groups. *p < 0.05, Significantly different from baseline (within group effect). †p < 0.05, Significantly different from the control or comparison group; TNF-α: tumor necrosis factor-α; IL-1β: Interleukin-1β; IL-2: Interleukin-2; IL-6: Interleukin-6; IL-8: Interleukin-8; CRP: C-reactive protein; IGF-1: Insulin-like growth factor 1; TRE: Time-restricted eating; eTRE: Early TRE; mTRE: Mid-day TRE; MetSyn: Metabolic syndrome; PCOS: Polycystic ovary syndrome.

### Table 3. Summary of studies on the impact of Ramadan fasting on inflammatory markers.

| Authors/Year/Country | Duration | Participants | Study Design | MMP-9 | TNF-α | IL-1β | IL-2 | IL-6 | IL-8 | IL-10 | CRP | IGF-1 |
|----------------------|----------|---------------|--------------|-------|-------|-------|------|------|------|------|-----|-------|
| Aliasghari et al., 2017 [76] Iran | 30-d | 83 patients with NAFLD | Observational Ramadan fasting 1. Ramadan fasting (n = 42) 2. Control (n = 41) | - | - | - | - | - | 1. ↓*† | 1. ↓*† hs-CRP | - |
| Mohammad zade et al., 2017 [77] Iran | 30-d | 23 healthy men | Observational Ramadan fasting | - | - | - | - | - | Ø | - | Ø | - |
| Authors/Year/Country | Duration | Participants | Study Design | MMP-9 | TNF-\(\alpha\) | IL-1\(\beta\) | IL-2 | IL-6 | IL-8 | IL-10 | CRP | IGF-1 |
|---------------------|----------|--------------|-------------|-------|----------------|----------------|------|------|------|------|-----|------|
| Mushtaq et al., 2019 [78] Pakistan | 29-d | 110 normal, overweight, and obese men (n = 55) and women (n = 55) | Observational Ramadan fasting (1st vs. 29th day of Ramadan just before Iftar) + dietary recommendation (oily foods prohibited at Iftar (breaking of fast time), plus white oats provided (bran diet) for Sahar (onset of fasting time) meal | - | ↓16% * Ψ men | ↓11% * Ψ women | - | - | - | - | - | - |
| Almeneessier et al., 2019 [79] Saudi Arabia | 14-d | 12 healthy men | Single arm Ramadan fasting (from dawn to sunset) | - | - | - | ↓* | - | - | - | - | - | - |
| Rahbar et al., 2019 [80] Saudi Arabia | 30-d | 34 healthy men | Observational Ramadan fasting | - | - | - | ↓* | - | - | - | - | - | ↓* |
| Faris et al., 2019 [81] UAE | 30-d | 57 overweight and obese adults | Observational Ramadan fasting | - | - | - | - | ↓* | - | - | ↑* | - | ↓* |
| Mansoor et al., 2020 [81] Iraq | 21-d | 20 healthy young women aged 19–20 y | Observational Ramadan fasting | - | - | - | - | ↓* | - | - | - | - | - |
| Lubis and Pase. 2020 [83] Indonesia | 30-d | 30 obese adults | Observational Ramadan fasting | - | - | - | - | - | - | - | - | - | - |
| Zouhal et al., 2020 [84] Tunisia | 30-d | 28 obese men | RCT: 1. Ramadan fasting 2. Control | - | 1. ↓ † | - | - | 1. ↓ † | - | 1. Ø | - | 2. Ø |
| Riat et al., 2021 [85] Germany | 27–29-d | 34 healthy adults | Observational Ramadan fasting (17–18 h) | - | - | - | - | - | - | - | - | - |

-: Not measured. Ø: Non-significant change between groups. * \(p < 0.05\), Significantly different from baseline (within group effect). † \(p < 0.05\), Significantly different from the control or comparison group. Ψ \(p < 0.05\), Significantly different from T2. MMP-9: Matrix metalloproteinase; TNF-\(\alpha\): tumor necrosis factor -\(\alpha\); IL-1\(\beta\): Interleukin-1\(\beta\); IL-2: Interleukin-2; IL-6: Interleukin-6; IL-8: Interleukin-8; IL-10: Interleukin-10; CRP: C-reactive protein; IGF-1: Insulin-like growth factor 1; NAFLD: Non-alcoholic fatty liver disease. Ψ: Significant reduction in only obese group (30 men, 30 women).
| Authors/Year/Country | Duration | Participants | Study Design | TNF-α | IL-1β | IL-2 | IL-4 | IL-5 | IL-6 | IL-13 | IL-17 | IL-22 | CRP | IFN-γ | CD40 Ligand | IGF-1 |
|----------------------|----------|--------------|--------------|-------|-------|------|------|------|------|-------|-------|-------|-----|-------|-------------|-------|
| Trepanowski et al., 2018 [86] US | 24 weeks | 69 overweight and obese | RCT: 1. ADF (25% energy needs on fast days, 125% on fed days) 2. CR (75% energy needs daily) 3. Control (100% energy needs daily) | 1. Ø | 2. Ø | - | - | - | - | 1. Ø | 2. Ø | - | - | - | - | - | - |
| Bowen et al., 2018 [87] Australia | 24 weeks | 162 overweight and obese adults | RCT: 1. High protein, ADF + CR (1 Ad lib intake d/wk) 2. CR | - | - | - | - | - | - | - | - | - | - | - | 1. ↓19* hs-CRP | - | - | 2. Ø |
| Schübel et al., 2018 [28] Germany | 12 weeks | 144 overweight and obese adults | RCT: 5:2 vs. CR and control +38 wk (12 wk maintenance + 26 wk follow up) | - | - | - | - | - | - | - | - | - | - | - | - | Ø | - | - | 2. Ø |
| Sundfor et al., 2018 [88] Norway | 52 weeks | 112 obese adults | RCT: 5:2 diet vs. CR + Med diet | - | - | - | - | - | - | - | - | - | - | - | Ø | - | - | - | - |
| Cho et al., 2019 [89] South Korea | 8 weeks | 31 overweight and obese adults | RCT: ADF vs. usual diet with or without exercise | - | - | - | - | - | - | - | - | - | - | - | - | Ø | - | - | - | - |
| Pinto et al., 2019 [90] UK | 4 weeks | 43 adults with central obesity | RCT: 1. 5:2 diet 2. CR | 1. ↓18% * 2. Ø | 1. Ø | - | - | - | 1. Ø | 2. Ø | - | - | - | - | - | - | - | - | 2. Ø |
| Razavi et al., 2021 [91] Iran | 17 weeks | 75 adults with MetSyn | RCT: 1. ADF (400–600 kcal on fast days) 2. CR (75% energy restriction daily) | 1. Ø | 2. Ø | - | - | - | - | 1. Ø | 2. Ø | - | - | - | - | - | - | - | 1. ↓46% hs-CRP | - | - | 2. ↓26% * |
Table 4. Cont.

| Authors/Year/Country | Duration | Participants | Study Design | TNF-α | IL-1β | IL-2 | IL-4 | IL-5 | IL-6 | IL-13 | IL-17 | IL-22 | CRP | IFN-γ | CD40 Ligand | IGF-1 |
|----------------------|----------|--------------|--------------|-------|-------|------|------|------|------|-------|-------|------|------|------|-----------|-------|
| Han et al., 2021     | 1-day    | 20 adults    | Single arm: 24-h prolonged fasting vs. post-prandial response, 3 h after isocaloric breakfast (500 kcal) | -     | ↓*    | ↓*   | ↓*   | -    | -    | ↓*   | -     | -     | -    | -    | -     | -       |
| [94] US              |          |              |              |       |       |      |      |      |      |       |       |      |      |      |          |
| Han et al., 2021     | 1-day    | 21 adults    | Single arm: 24-h prolonged fasting vs. post-prandial response, 3 h after isocaloric breakfast (500 kcal) | -     | -     | Ø    | -    | -    | ↓*   | -    | -     | -     | -    | -    | -     | -       |
| [93] US              |          |              |              |       |       |      |      |      |      |       |       |      |      |      |          |
| Bartholomew et al., 2021 [38] US | 26 weeks | 103 adults; ≥1 MetSyn component or T2D | RCT: 1. 5:2 diet for 4 weeks; followed by fasting once a week for 22 weeks 2. Ad libitum control | -     | -     | -    | -    | -    | -    | -    | -     | -     | -    | -    | -     | -       |
| Guo et al., 2021     | 8 weeks  | 39 adults with MetSyn | RCT: 1. 5:2 diet (two days fasting per week) 2. Control | Ø     | -     | -    | -    | -    | -    | -    | -     | -     | -    | -    | -     | -       |
| [92] China           |          |              |              |       |       |      |      |      |      |       |       |      |      |      |          |

*: Not measured. Ø: Non-significant change between groups. * p < 0.05, Significantly different from baseline (within group effect). † p < 0.05, Significantly different from the control or comparison group. TNF-α: tumor necrosis factor-α; IL-1β: Interleukin-1β; IL-2: Interleukin-2; IL-4: Interleukin-4; IL-5: Interleukin-5; IL-6: Interleukin-6; IL-13: Interleukin-13; IL-17: Interleukin-17; IL-22: Interleukin-22; CRP: C-reactive protein; IFN-γ: Interferon gamma; IGF-1: Insulin-like growth factor 1; ADF: Alternate-day fasting; CR: Caloric restriction; MetSyn: Metabolic syndrome; Med diet: Mediterranean diet; T2D: Type 2 diabetes.
4.2. TNF-α

Studies of the impact of different IF regimens on TNF-α have reported inconsistent results (see Tables 2–4). Early TRE and Ramadan IF have been shown to significantly improve TNF-α levels vs. control and/or baseline, while mid-day TRE has not shown such improvements in two out of the three TRE trials included in this review [32,72]. Likewise, ADF appears to be ineffective for reducing plasma TNF-α, as two ADF trials in adults with overweight or obesity and metabolic syndrome, which tested changes in TNF-α have not demonstrated significant improvements following ADF regimens [86,91]. Of the two twice-weekly fasting studies which assessed TNF-α, one RCT in 43 adults with central obesity showed significant decreases (−18%) vs. baseline, but no between group differences when compared with a caloric restriction arm [90].

4.3. C-Reactive Protein

There has also been inconsistency in the results of various trials of IF regimens on hs-CRP levels, with most studies indicating no effects (see Tables 2–4). Of the seven TRE studies included in this review, only two trials (4 to 5 week durations) reported significant improvements in hs-CRP levels (−45% and −42%) in overweight and obese participants vs. a control or as compared with baseline [96,97]. In two TRE studies, only hs-CRP was examined and was unchanged [95,98]. Hs-CRP levels were not altered in short-term (8 weeks) ADF studies, whereas longer duration trials (17 and 24 weeks; with a high protein diet) have significantly decreased hs-CRP (−48% and −19%) versus CR or baseline, respectively [87,89,91]. In addition, twice-weekly fasting did not appear to affect hs-CRP levels [28,38,88,90]. Furthermore, only one observational Ramadan IF study in 83 patients with non-alcoholic fatty liver disease, has shown significant decreases in hs-CRP levels vs. control and baseline following Ramadan IF after 30 days [76].

4.4. IGF-1

IGF-1 levels remain unchanged with most IF trials that recruited participants with overweight and obesity. In athletes, however, two RCTs conducted by Moro et al. reported significant reductions in IGF-1 levels with TRE as compared to control and baseline after both 4 weeks and 12 months [72,74]. IGF-1 significantly increased (34%) in a single arm trial of early TRE (8 a.m.–4 p.m.) in 15 overweight and obese women with Polycystic ovary syndrome [97]. There is lack of consistency in IGF-1 results of observational Ramadan IF studies (see Table 3).

4.5. Interferon Gamma and Other Inflammatory Markers

Interferon gamma (IFN-γ), a proinflammatory cytokine that plays a significant role in immune responses, has been investigated in only two 24-h prolonged fasting studies by Han and colleagues. These studies indicate that IFN-γ levels were significantly reduced when compared with 3 h after refeeding with isocaloric breakfast meal (500 kcal) in a total of adults who fasted for 24 h [93,94]. Matrix metalloproteinase 9 (MMP-9) was assessed in one observational Ramadan IF study in 34 healthy adults [85]. The levels MMP-9 were determined at five different time periods within 27–29 days of fasting during the month of Ramadan. While MMP-9 levels remained unchanged from mid-month (days 14–16) to one week after Ramadan, they were significantly lower vs. baseline at the one month after Ramadan timepoint (see Table 3). Changes in CD40 ligand have also been tested in two studies, with only one 8-week RCT of twice-per-week fasting in 39 adults with metabolic syndrome, demonstrating a meaningful reduction in CD40 ligand vs. control after 8 weeks [92].

4.6. Oxidative Stress

8-Isoprostane is a marker of oxidative stress that is associated with COVID-19 [99]. To date, only two trials have examined 8-Isoprostane levels following TRE [30,32], with significant decreases in 8-Isoprostane reported in both studies compared to both control
and baseline. Early TRE (eTRE; 6-hr eating window, last meal before 3 pm) showed a 14% reduction in 8-Isoprostane in the eTRE arm versus control (12-hr. eating window) in 12 prediabetic men after 5 weeks. In addition, restricting eating windows to four (3–7 p.m.) and six hours (1–7 p.m.) significantly reduced 8-Isoprostane levels in both groups (37% and 34%, respectively) vs. control (ad libitum intake) in adults with obesity following 8 weeks [32]. In contrast, short-term (6 weeks) eucaloric TRE with self-selected eating windows did not significantly enhance plasma oxidized LDL or the oxidized total LDL ratio in non-obese healthy older adults [73].

5. Conclusions and Future Directions

Evidence suggests that intermittent fasting and supplementation with vitamin D, and nutraceuticals including quercetin, n-3 fatty acids, and probiotics, impact inflammation in canonical pathways related to both NCDs and infectious diseases including COVID-19 and, thus, should reduce COVID-19 severity. A lack of high-quality evidence exists for the support of such efficacy of supplementation with vitamins A, B, and C, as well as zinc in COVID-19 patients. Further investigation of these fasting and supplementation effects is indicated. Observational studies report that some diets (e.g., the Mediterranean diet, plant-based diets) may reduce SARS-CoV-2 severity, potentially—at least in part—because the foods contain antioxidants and other components with anti-inflammatory properties [100–103], but further research is needed on such diets.

Ultimately, the impact of intermittent energy restriction methods on inflammation during energy restriction may be acute but transient, contrasting with longer-term persistent changes to basal levels of inflammation. Future randomized controlled trials are needed to elucidate the effects of intermittent fasting on NCDs and on inflammatory host responses to infection.

Author Contributions: Conceptualization, B.D.H. and A.E.; methodology, A.E., B.D.H. and S.K.R.; writing—original draft preparation, A.E. and B.D.H.; writing—review and editing, B.D.H. and S.K.R.; supervision, B.D.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: BDH is PI of intermittent fasting-related grants from the Intermountain Research and Medical Foundation, a member of the scientific advisory boards of Opsis Health and Lab Me Analytics, an inventor of clinical risk scores licensed by Intermountain Healthcare to Allucceo and CareCentra, and PI of grants from AstraZeneca and the Patient-Centered Outcomes Research Institute. The authors declare no other potential conflict of interest.

References

1. da Silva, S.J.R.; Kohl, A.; Pena, L.; Pardee, K. Recent Insights into SARS-CoV-2 Omicron Variant. *Rev. Med. Virol.* 2022, e2373. [CrossRef] [PubMed]
2. Araf, Y.; Akter, F.; Tang, Y.-D.; Fatemi, R.; Parvez, M.S.A.; Zheng, C.; Hussain, M.G. Omicron Variant of SARS-CoV-2: Genomics, Transmissibility, and Responses to Current COVID-19 Vaccines. *J. Med. Virol.* 2022, 94, 1825–1832. [CrossRef] [PubMed]
3. Menni, C.; May, A.; Polidori, L.; Louca, P.; Wolf, J.; Capdevila, J.; Hu, C.; Ourselin, S.; Steves, C.J.; Valdes, A.M.; et al. COVID-19 Vaccine Waning and Effectiveness and Side-Effects of Boosters: A Prospective Community Study from the ZOE COVID Study. *Lancet Infect. Dis.* 2022, 22, 1002–1010. [CrossRef]
4. Webb, B.J.; Peltan, I.D.; Jensen, P.; Hoda, D.; Hunter, B.; Silver, A.; Starr, N.; Buckel, W.; Grisel, N.; Hummel, E.; et al. Clinical Criteria for COVID-19-Associated Hyperinflammatory Syndrome: A Cohort Study. *Lancet Rheumatol.* 2020, 2, e754–e763. [CrossRef]
5. Forcados, G.E.; Muhammad, A.; Oladipo, O.O.; Makama, S.; Meseko, C.A. Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants. *Front. Cell Infect. Microbiol.* 2021, 11, 654813. [CrossRef] [PubMed]
14. Martins, T.B.; Anderson, J.L.; Muhlestein, J.B.; Horne, B.D.; Carlquist, J.F.; Roberts, W.L.; Carlquist, J.F. Risk Factor Analysis of...

13. Jandaghi, P.; Hosseini, Z.; Chilibeck, P.; Hanley, A.J.; Deguire, J.R.; Bandy, B.; Pahwa, P.; Vatanparast, H. The Role of Immunomodulatory Nutrients in Alleviating Complications Related to SARS-CoV-2: A Scoping Review. Adv. Nutr. 2021, 13, nmab128. [CrossRef] [PubMed]

12. Zeng, F.; Huang, Y.; Guo, Y.; Yin, M.; Chen, X.; Xiao, L.; Deng, G. Association of Inflammatory Markers with the Severity of COVID-19: A Meta-Analysis. Int. J. Infect. Dis. 2020, 96, 467–474. [CrossRef] [PubMed]

11. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [CrossRef] [PubMed]

10. Poggiali, E.; Zaino, D.; Immovilli, P.; Rovero, L.; Losi, G.; Dacremo, A.; Nuccetelli, M.; Vadacca, G.B.; Guidetti, D.; Vercelli, A.; et al. Lactate Dehydrogenase and C-Reactive Protein as Predictors of Respiratory Failure in COVID-19 Patients. Clin. Chim. Acta 2020, 509, 135–138. [CrossRef] [PubMed]

9. Gelzo, M.; Cacciapuoti, S.; Pinchera, B.; De Rosa, A.; Cernera, G.; Scialò, F.; Comegna, M.; Mormile, M.; Fabbrocini, G.; Parrella, R.; et al. Matrix Metalloproteinases (MMP) 3 and 9 as Biomarkers of Severity in COVID-19 Patients. Sci. Rep. 2022, 12, 1212. [CrossRef] [PubMed]

8. Halim, C.; Mirza, A.F.; Sari, M.I. The Association between TNF-α, IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis. Pathogens 2022, 11, 195. [CrossRef] [PubMed]

7. Jandaghi, P.; Hosseini, Z.; Chilibeck, P.; Hanley, A.J.; Deguire, J.R.; Bandy, B.; Pahwa, P.; Vatanparast, H. The Role of Immunomodulatory Nutrients in Alleviating Complications Related to SARS-CoV-2: A Scoping Review. Adv. Nutr. 2021, 13, nmab128. [CrossRef] [PubMed]

6. Liu, F.; Li, L.; Xu, M.; Wu, J.; Luo, D.; Zhu, Y.; Li, B.; Song, X.; Zhou, X. Prognostic Value of Interleukin-6, C-Reactive Protein, and Procalcitonin in Patients with COVID-19. J. Clin. Virol. 2020, 127, 104370. [CrossRef]

5. Jandaghi, P.; Hosseini, Z.; Chilibeck, P.; Hanley, A.J.; Deguire, J.R.; Bandy, B.; Pahwa, P.; Vatanparast, H. The Role of Immunomodulatory Nutrients in Alleviating Complications Related to SARS-CoV-2: A Scoping Review. Adv. Nutr. 2021, 13, nmab128. [CrossRef] [PubMed]

4. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction among Apparently Healthy Men. Circulation 2000, 101, 1767–1772. [CrossRef] [PubMed]

3. Martins, T.B.; Anderson, J.L.; Muhlestein, J.B.; Horne, B.D.; Carlquist, J.F.; Roberts, W.L.; Carlquist, J.F. Risk Factor Analysis of Plasma Cytokines in Patients with Coronary Artery Disease by a Multiplexed Fluorescent Immunoassay. Am. J. Clin. Pathol. 2006, 125, 906–913. [CrossRef] [PubMed]

2. Elimam, H.; Abdulla, A.M.; Taha, I.M. Inflammatory Markers and Control of Type 2 Diabetes Mellitus. Diabetes Metab. Syndr. 2019, 13, 800–804. [CrossRef] [PubMed]

1. Luc, K.; Schramm-Luc, A.; Guzik, T.J.; Mikolajczyk, T.P. Oxidative Stress and Inflammatory Markers in Prediabetes and Diabetes. J. Physiol. Pharm. 2019, 70, 70. [CrossRef] [PubMed]
29. Carter, S.; Clifton, P.M.; Keogh, J.B. Effect of Intermittent Compared With Continuous Energy Restricted Diet on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Noninferiority Trial. *JAMA Netw. Open* 2018, 1, e180756. [CrossRef] [PubMed]

30. Sutton, E.F.; Beyl, R.; Early, K.S.; Cofalu, W.T.; Ravussin, E.; Peterson, C.M. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. *Cell Metab.* 2018, 27, 1212–1221.e3. [CrossRef]

31. Hutchison, A.T.; Liu, B.; Wood, R.E.; Vincent, A.D.; Thompson, C.H.; O'Callaghan, N.J.; Wittert, G.A.; Heilbronn, L.K. Effects of Intermittent Versus Continuous Energy Intakes on Insulin Sensitivity and Metabolic Risk in Women with Overweight. *Obes. (Silver Spring)* 2019, 27, 50–58. [CrossRef] [PubMed]

32. Cienfuegos, S.; Gabel, K.; Kalam, F.; Ezpeleta, M.; Wiseman, E.; Pavlou, V.; Lin, S.; Oliveira, M.L.; Varady, K.A. Effects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity. *Cell Metab.* 2020, 32, 366–378.e3. [CrossRef] [PubMed]

33. Hannan, M.A.; Rahman, M.A.; Rahman, M.S.; Sohag, A.A.M.; Dash, R.; Hossain, K.S.; Farjana, M.; Uddin, M.J. Intermittent Fasting, a Possible Priming Tool for Host Defense against SARS-CoV-2 Infection: Crosstalk among Calorie Restriction, Autophagy and Immune Response. *Immunol. Lett.* 2022, 226, 38–45. [CrossRef] [PubMed]

34. Zabetakis, I.; Lordan, R.; Norton, C.; Tsoupras, A. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation. *Nutrients* 2020, 12, 1466. [CrossRef] [PubMed]

35. Ealey, K.N.; Phillips, J.; Sung, H.-K. COVID-19 and Obesity: Fighting Two Pandemics with Intermittent Fasting. *Trends Endocrinol. Metab.* 2021, 32, 706–720. [CrossRef] [PubMed]

36. Bhatti, S.I.; Mindikoglu, A.L. The Impact of Dawn to Sunset Fasting on Immune System and Its Clinical Significance in COVID-19 Pandemic. *Metab. Open* 2022, 13, 100162. [CrossRef]

37. Jamshed, H.; Beyl, R.A.; Della Manna, D.L.; Yang, E.S.; Ravussin, E.; Peterson, C.M. Early Time-Restricted Feeding Improves 24-Hour Glucose Levels and Affects Markers of the Circadian Clock, Aging, and Autophagy in Humans. *Nutrients* 2019, 11, 1234. [CrossRef] [PubMed]

38. Bartholomew, C.L.; Muhlestein, J.B.; May, H.T.; Le, V.T.; Galenko, O.; Garrett, K.D.; Brunker, C.; Hopkins, R.O.; Carlquist, J.E.; Knowlton, K.U.; et al. Randomized Controlled Trial of Once-per-Week Intermittent Fasting for Health Improvement: The WONDERFUL Trial. *Eur. Heart J. Open* 2021, 1, oeb026. [CrossRef]

39. Wu, R.; Wang, L.; Kuo, H.-C.D.; Shannar, A.; Peter, R.; Chou, P.J.; Li, S.; Hudliker, R.; Liu, X.; Liu, Z.; et al. An Update on Current Therapeutic Drugs Treating COVID-19. *Curr. Pharmacol. Rep.* 2020, 6, 56–70. [CrossRef]

40. Martineau, A.R.; Jolliffe, D.A.; Cooper, L.R.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; et al. Vitamin D Supplementation to Prevent Acute Respiratory Tract Infections: Systematic Review and Meta-Analysis of Individual Participant Data. *BMJ* 2017, 356, i6583. [CrossRef]

41. Beigmohammadi, M.T.; Bitarafan, S.; Hoseindokht, A.; Abdollahi, A.; Amoozadeh, L.; Soltani, D. The Effect of Supplementation with Vitamins A, B, C, D, and E on Disease Severity and Inflammatory Responses in Patients with COVID-19: A Randomized Clinical Trial. *Trials* 2021, 22, 802. [CrossRef] [PubMed]

42. Darban, M.; Malek, F.; Memarian, M.; Gohari, A.; Kiani, A.; Emadi, A.; Lavaf, S.; Bagheri, B. Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome Due to Coronavirus Infection: A Pilot Randomized Trial. *J. Cell Mol. Anesth.* 2021, 6, 164–167. [CrossRef]

43. Grant, W.B.; Lahore, H.; McDonnell, S.L.; Baggerly, C.A.; French, C.B.; Aliano, J.L.; Bhattoa, H.P.; Kandakatla, M.; et al. Impact of Daily High Dose Oral Vitamin D Therapy on the Inflammatory Markers in Patients with COVID-19 Disease. *Sci. Rep.* 2021, 11, 10641. [CrossRef]

44. Dror, A.A.; Morozov, N.; Daoud, A.; Namir, Y.; Yakir, O.; Shachar, Y.; Lifshitz, M.; Segal, E.; Fisher, L.; Mizrachi, M.; et al. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial. *Nutrients* 2021, 13, 2170. [CrossRef]

45. Sabico, S.; Enani, M.A.; Sheshah, E.; Aljohani, N.J.; Aldisi, D.A.; Alotaibi, N.H.; Alshingetti, N.; Alomar, S.Y.; Alnaami, A.M.; Amer, O.E.; et al. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial. *Nutrients* 2021, 13, 2170. [CrossRef]

46. Katz, J.; Yue, S.; Xue, W. Increased Risk for COVID-19 in Patients with Vitamin D Deficiency. *Nutrition* 2021, 84, 111106. [CrossRef] [PubMed]

47. Annweiler, C.; Beaudenon, M.; Simon, R.; Guenet, M.; Otekpo, M.; Célarié, T.; Gautier, J. GERIA-COVID study group Vitamin D Supplementation Prior to or during COVID-19 Associated with Better 3-Month Survival in Geriatric Patients: Extension Phase of the GERIA-COVID Study. *J. Steroid. Biochem. Mol. Biol.* 2021, 213, 105985. [CrossRef]

48. Sabico, S.; Enani, M.A.; Sheshah, E.; Aljohani, N.J.; Aldisi, D.A.; Alotaibi, N.H.; Alshingetti, N.; Alomar, S.Y.; Alnaami, A.M.; Amer, O.E.; et al. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial. *Nutrients* 2021, 13, 2170. [CrossRef]

49. Lakkireddy, M.; Gadiga, S.G.; Malathi, R.D.; Karra, M.L.; Raju, I.S.S.V. P.M.; Ragini; Chinapaka, S.; Baba, K.S.S.S.; Kandakatla, M. Impact of Daily High Dose Oral Vitamin D Therapy on the Inflammatory Markers in Patients with COVID-19 Disease. *Sci. Rep.* 2021, 11, 10641. [CrossRef] [PubMed]

50. Rastogi, A.; Bhansali, A.; Khare, N.; Suri, V.; Yaddanapudi, N.; Sachdeva, N.; Puri, G.D.; Malhotra, P. Short Term, High-Dose Vitamin D Supplementation for COVID-19 Disease: A Randomised, Placebo-Controlled, Study (SHADE Study). *Postgrad. Med. J.* 2022, 98, 87–90. [CrossRef]
51. Fernandes, A.L.; Murai, L.H.; Reis, B.Z.; Sales, L.P.; Santos, M.D.; Pinto, A.J.; Goessler, K.F.; Duran, C.S.C.; Silva, C.B.R.; Franco, A.S.; et al. Effect of a Single High Dose of Vitamin D3 on Cytokines, Chemokines, and Growth Factor in Patients with Moderate to Severe COVID-19. Am. J. Clin. Nutr. 2022, 115, 790–798. [CrossRef] [PubMed]

52. Cannata-Andia, J.B.; Díaz-Sottolano, A.; Fernández, P.; Palomo-Antequera, C.; Herrero-Puente, P.; Mouzo, R.; Carrillo-López, N.; Panizo, S.; Ibáñez, G.H.; Cusumano, C.A.; et al. A Single-Oral Bolus of 100,000 IU of Cholecalciferol at Hospital Admission Did Not Improve Outcomes in the COVID-19 Disease: The COVID-VIT-D-a Randomised Multicentre International Clinical Trial. BMC Med. 2022, 20, 83. [CrossRef] [PubMed]

53. Murai, I.H.; Fernandes, A.L.; Sales, L.P.; Pinto, A.J.; Goessler, K.F.; Duran, C.S.C.; Silva, C.B.R.; Franco, A.S.; Macedo, M.B.; Dalmolin, H.H.H.; et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Randomised Clinical Trial. JAMA 2021, 325, 1053–1060. [CrossRef] [PubMed]

54. Thomas, E.A.; Zaman, A.; Sloggett, K.J.; Steinke, S.; Grau, L.; Catenacci, V.A.; Cornier, M.-A.; Rynders, C.A. Early Time-Restricted Eating Compared with Daily Caloric Restriction: A Randomized Trial in Adults with Obesity. Obesity (Silver Spring) 2022, 30, 1027–1038.

55. Patel, O.; Chinni, V.; El-Khoury, J.; Perera, M.; Neto, A.S.; McDonald, C.; See, E.; Jones, D.; Bolton, D.; Bellomo, R.; et al. A Pilot Double-blind Safety and Feasibility Randomized Controlled Trial of High-dose Intravenous Zinc in Hospitalized COVID-19 Patients. J. Med. Virol. 2021, 93, 3261–3267. [CrossRef]

56. Balboni, E.; Zagroni, F.; Filippini, T.; Fairweather-Tait, S.J.; Vinceti, M. Zinc and Selenium Supplementation in COVID-19 Prevention and Treatment: A Systematic Review of the Experimental Studies. J. Trace Elem. Med. Biol. 2022, 71, 126956. [CrossRef]

57. Abd-Elsalam, S.; Soliman, S.; Esmail, E.S.; Khalaf, M.; Mostafa, E.F.; Medhat, M.A.; Ahmed, O.A.; El Ghafar, M.S.A.; Alboraie, M.; Hassany, S.M. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: A Randomized, Multicenter Trial. Biol. Trace Elem. Res. 2021, 199, 3642–3646. [CrossRef]

58. Di Pierro, F.; Derosa, G.; Maffioli, P.; Bertuccioli, A.; Togni, S.; Riva, A.; Allegrini, P.; Khan, A.; Khan, S.; Khan, B.A.; et al. Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. Int. J. Gen. Med. 2021, 14, 2359–2366. [CrossRef]

59. Doaei, S.; Gholami, S.; Rastgoo, S.; Gholamalizadeh, M.; Bourbou, F.; Bagheri, S.E.; Samipoor, F.; Akbari, M.E.; Shadnouz, M.; Ghorat, F.; et al. The Effect of Omega-3 Fatty Acid Supplementation on Clinical and Biochemical Parameters of Critically Ill Patients with COVID-19: A Randomized Clinical Trial. J. Transl. Med. 2021, 19, 128. [CrossRef]

60. Sedighiyani, M.; Abdollahi, H.; Karimi, E.; Badeli, M.; Erfanian, R.; Raeesi, S.; Hashemi, R.; Vahabi, Z.; Asanjarani, B.; Mansouri, F.; et al. Omega-3 Polysaturated Fatty Acids Supplementation Improve Clinical Symptoms in Patients with COVID-19: A Randomized Clinical Trial. Int. J. Clin. Pr. 2021, 75, e14854. [CrossRef]

61. Shohan, M.; Nashibi, R.; Mahmoudian-Sani, M.-R.; Abolnezhadian, F.; Ghafourian, M.; Alavi, S.M.; Sharhani, A.; Khodadadi, A. The Therapeutic Efficacy of Quercetin in Combination with Antiviral Drugs in Hospitalized COVID-19 Patients: A Randomized Controlled Trial. Eur. J. Pharmacol. 2022, 914, 174615. [CrossRef] [PubMed]

62. Pimentel, R.F.W.; Silva, A.P.; Santana, A.I.C.; Silva, D.D.S.E.; Ramos, M.D.S.; de Souza, M.C.; Suen, V.M.M.; Ahmed, O.A.; Al Ghafar, M.S.A.; Alboraie, M.; et al. The Therapeutic Efficacy of Quercetin in Combination with Antiviral Drugs in Hospitalized COVID-19 Patients: A Randomized Controlled Trial. Br. J. Clin. Pharm. 2023, 85, 645–662. [CrossRef]

63. Calder, P.C. Omega-3 Polysaturated Fatty Acids and Inflammatory Processes: Nutrition or Pharmacology? Br. J. Clin. Pharm. 2013, 75, 645–662. [CrossRef]

64. Calder, P.C. Marine Omega-3 Fatty Acids and Inflammatory Processes: Effects, Mechanisms and Clinical Relevance. Biochim. Biophys. Acta 2015, 1851, 469–484. [CrossRef]

65. Wu, W.; Li, R.; Li, X.; He, J.; Jiang, S.; Liu, S.; Yang, J. Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry. Viruses 2015, 8, 6. [CrossRef]

66. Liu, Y.; Yu, C.; Ji, K.; Wang, X.; Li, X.; Xie, H.; Wang, Y.; Huang, Y.; Qi, D.; Fan, H. Quercetin Reduces TNF-α-Induced Mesangial Cell Proliferation and Inhibits PTX3 Production: Involvement of NF-κB Signaling Pathway. Phytother. Res. 2019, 33, 2401–2408. [CrossRef]

67. Margolin, L.; Luchins, J.; Margolin, D.; Margolin, M.; Lefkowitz, S. 20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment. J. Evid.-Based Integr. Med. 2021, 26, 2515690X211026193. [CrossRef]

68. King, S.; Glanville, J.; Sanders, M.E.; Fitzgerald, A.; Varley, D. Effectiveness of Probiotics on the Duration of Illness in Healthy Children and Adults Who Develop Common Acute Respiratory Infectious Conditions: A Systematic Review and Meta-Analysis. Br. J. Nutr. 2014, 112, 41–54. [CrossRef]

69. Horne, B.D.; May, H.T.; Muhlestein, J.B.; Le, V.T.; Bair, T.L.; Knowlton, K.U.; Anderson, J.L. Association of Periodic Fasting with Lower Severity of COVID-19 Outcomes in the SARS-CoV-2 Prevaccine Era: An Observational Cohort from the INSPIRE Registry. BMJ Nutr. Prev. Health 2022, e00462. [CrossRef]
72. Moro, T.; Tinsley, G.; Pacelli, F.Q.; Marcolin, G.; Bianco, A.; Paoli, A. Twelve Months of Time-Restricted Eating and Resistance Training Improves Inflammatory Markers and Cardiometabolic Risk Factors. *Med. Sci. Sports Exerc.* 2021, 53, 2577–2585. [CrossRef] [PubMed]

73. Martens, C.R.; Rossman, M.J.; Mazzo, M.R.; Jankowski, L.R.; Nagy, E.E.; Denman, B.A.; Richey, J.J.; Johnson, S.A.; Ziembra, B.P.; Wang, Y.; et al. Short-Term Time-Restricted Feeding Is Safe and Feasible in Non-Obese Healthy Midlife and Older Adults. *Geroscience* 2020, 42, 667–686. [CrossRef] [PubMed]

74. Moro, T.; Tinsley, G.; Longo, G.; Grigolotto, D.; Bianco, A.; Ferraris, C.; Guglielmetti, M.; Veneto, A.; Tagliabue, A.; Marcolin, G.; et al. Time-Restricted Eating Effects on Performance, Immune Function, and Body Composition in Elite Cyclists: A Randomized Controlled Trial. *J. Int. Soc. Sports Nutr.* 2020, 17, 65. [CrossRef] [PubMed]

75. Xie, Z.; Sun, Y.; Ye, Y.; Hu, D.; Zhang, H.; He, Z.; Zhao, H.; Yang, H.; Mao, Y. Randomized Controlled Trial for Time-Restricted Eating in Healthy Volunteers without Obesity. *Nat. Commun.* 2022, 13, 1003. [CrossRef] [PubMed]

76. Aliasghari, F.; Izadi, A.; Gargari, B.P.; Ebrahimi, S. The Effects of Ramadan Fasting on Body Composition, Blood Pressure, Glucose Metabolism, and Markers of Inflammation in NAFLD Patients: An Observational Trial. *J. Am. Coll. Nutr.* 2017, 36, 640–645. [CrossRef]

77. Mohammadzade, F.; Vakili, M.A.; Seyediniaki, A.; Amirkhanloo, S.; Farajolahi, M.; Akbari, H.; Eshghinia, S. Effect of Prolonged Fasting on Proinflammatory Cytokine Levels in Healthy Males: A Randomized Controlled Trial. *Int. J. Prev. Med.* 2021, 10, 697290. [CrossRef] [PubMed]

78. Mansoor, A.J.; Hussein, Y.; Jumaa, A.; Marbut, M.; Marbut, M.; Aljubori, A. Effect of Ramadan Fasting on Pro-Inflammatory Markers and Cardiometabolic Risk Factors. *Med. Sci. Cardiometab. Risk* 2020, 15, 18–26. [CrossRef]

79. Rahbar, A.R.; Safavi, E.; Rooholamini, M.; Jaafari, F.; Darvishi, S.; Rahbar, A. Effects of Intermittent Fasting during Ramadan on Insulin-like Growth Factor-1, Interleukin 2, and Lipid Profile in Healthy Muslims. *Int. J. Prev. Med.* 2019, 10, 7. [CrossRef]

80. Zouhal, H.; Bagheri, R.; Ashtary-Larky, D.; Wong, A.; Triki, R.; Hackney, A.C.; Laher, I.; Abderrahman, A.B. Effects of Ramadan Fasting on Lipid Profiles and Interleukin-6 in Obese Patients. *J. Endocrinol. Trop. Med. Infect. Dis.* (JETROMI) 2020, 2, 107–117. [CrossRef]

81. Bowen, J.; Brindal, E.; James-Martin, G.; Noakes, M. Randomized Trial of a High Protein, Partial Meal Replacement Program and Exercise on Cholesterol Metabolism in Overweight or Obese Adults: A Pilot Randomized Controlled Trial. *Clin. Nutr.* 2018, 37, 1871–1878. [CrossRef] [PubMed]

82. Guo, Y.; Luo, S.; Ye, Y.; Yin, S.; Fan, J.; Xia, M. Intermittent Fasting Improves Cardiometabolic Risk Factors and Alters Gut Microbiota in Metabolic Syndrome Patients. *J. Clin. Endocrinol. Metab.* 2021, 106, 64–79. [CrossRef]
93. Han, K.; Singh, K.; Rodman, M.J.; Hassanzadeh, S.; Wu, K.; Nguyen, A.; Huffstutler, R.D.; Seifuddin, F.; Dagur, P.K.; Saxena, A.; et al. Fasting-Induced FOXO4 Blunts Human CD4+ T Helper Cell Responsiveness. *Nat. Metab.* 2021, 3, 318–326. [CrossRef] [PubMed]

94. Han, K.; Singh, K.; Rodman, M.J.; Hassanzadeh, S.; Baumer, Y.; Huffstutler, R.D.; Chen, J.; Candia, J.; Cheung, F.; Stagliano, K.E.R.; et al. Identification and Validation of Nutrient State-Dependent Serum Protein Mediators of Human CD4+ T Cell Responsiveness. *Nutrients* 2021, 13, 1492. [CrossRef]

95. Wilkinson, M.J.; Manoogian, E.N.C.; Zadourian, A.; Lo, H.; Fakhouri, S.; Shoghi, A.; Wang, X.; Fleischer, J.G.; Navlakha, S.; Panda, S.; et al. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. *Cell Metab.* 2020, 31, 92–104.e5. [CrossRef] [PubMed]

96. Li, C.; Xing, C.; Zhang, J.; Zhao, H.; Shi, W.; He, B. Eight-Hour Time-Restricted Feeding Improves Endocrine and Metabolic Profiles in Women with Anovulatory Polycystic Ovary Syndrome. *J. Transl. Med.* 2021, 19, 148. [CrossRef] [PubMed]

97. McAllister, M.J.; Pigg, B.L.; Renteria, L.L.; Waldman, H.S. Time-Restricted Feeding Improves Markers of Cardiometabolic Health in Physically Active College-Age Men: A 4-Week Randomized Pre-Post Pilot Study. *Nutr. Res.* 2020, 75, 32–43. [CrossRef]

98. Kotarsky, C.J.; Johnson, N.R.; Mahoney, S.J.; Mitchell, S.L.; Schimek, R.L.; Stastny, S.N.; Hackney, K.J. Time-Restricted Eating and Concurrent Exercise Training Reduces Fat Mass and Increases Lean Mass in Overweight and Obese Adults. *Physiol. Rep.* 2021, 9, e14868. [CrossRef] [PubMed]

99. Soto, M.E.; Guarner-Lans, V.; Díaz-Díaz, E.; Manzano-Pech, L.; Palacios-Chavarria, A.; Valdez-Vázquez, R.R.; Aisa-Álvarez, A.; Saucedo-Orozco, H.; Pérez-Torres, I. Hyperglycemia and Loss of Redox Homeostasis in COVID-19 Patients. *Cells* 2022, 11, 932. [CrossRef]

100. Kim, H.; Rebholz, C.M.; Hegde, S.; LaFiura, C.; Raghavan, M.; Lloyd, J.F.; Cheng, S.; Seidelmann, S.B. Plant-based diets, pescatarian diets and COVID-19 severity: A population-based case-control study in six countries. *BMJ Nutr. Prev. Health* 2021, 4, 257–266. [CrossRef]

101. Perez-Araluce, R.; Martínez-González, M.; Gea, A.; Carlos, S. Components of the Mediterranean Diet and Risk of COVID-19. *Front. Nutr.* 2022, 8, 805333. [CrossRef] [PubMed]

102. Angelidi, A.M.; Kokkinos, A.; Katechaki, E.; Ros, E.; Mantzoros, C.S. Mediterranean diet as a nutritional approach for COVID-19. *Metabolism* 2021, 114, 154407. [CrossRef] [PubMed]

103. Ponzo, V.; Pellegrini, M.; D’Eusebio, C.; Biolo, F.; Goitre, I.; Buscemi, S.; Freia, S.; Ghigo, E.; Bo, S. Mediterranean Diet and SARS-CoV-2 Infection: Is There Any Association? A Proof-of-Concept Study. *Nutrients* 2021, 13, 1721. [CrossRef] [PubMed]